The impact of contour variation on tumour control probability in anal cancer by Jones, Michael et al.
University of Wollongong 
Research Online 
Faculty of Engineering and Information 
Sciences - Papers: Part B 
Faculty of Engineering and Information 
Sciences 
2018 
The impact of contour variation on tumour control probability in 
anal cancer 
Michael Jones 
University of Newcastle 
Jarad Martin 
University of Newcastle 
Kerwyn Y. Foo 
Chris O'Brien Lifehouse, kfoo@uow.edu.au 
Patrick Estoesta 
Chris O'Brien Lifehouse 
Lois C. Holloway 
University of Wollongong, loish@uow.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/eispapers1 
 Part of the Engineering Commons, and the Science and Technology Studies Commons 
Recommended Citation 
Jones, Michael; Martin, Jarad; Foo, Kerwyn Y.; Estoesta, Patrick; Holloway, Lois C.; and Jameson, Michael, 
"The impact of contour variation on tumour control probability in anal cancer" (2018). Faculty of 
Engineering and Information Sciences - Papers: Part B. 1710. 
https://ro.uow.edu.au/eispapers1/1710 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
The impact of contour variation on tumour control probability in anal cancer 
Abstract 
Background: While intensity modulated radiotherapy (IMRT) has been widely adopted for the treatment of 
anal cancer (AC), the added contour complexity poses potential risks. This study investigates the impact 
of contour variation on tumour control probability (TCP) when using IMRT for AC. Methods: Nine 
Australian centres contoured a single computed tomography dataset of a patient with AC. The same 
optimised template-based IMRT planning protocol was applied to each contour set to generate nine 
representative treatment plans and their corresponding dose volume histograms. A geometric analysis 
was performed on all contours. The TCP was calculated for each plan using the linear quadratic and 
logitEUD model. Results: The median concordance index (CI) for the bladder, head and neck of femur, 
bone marrow, small bowel and external genitalia was 0.94, 0.88, 0.84, 0.65 and 0.65, respectively. The 
median CI for the involved nodal, primary tumour and elective clinical target volumes were 0.85, 0.77 and 
0.71, respectively. Across the nine plans, the TCP was not significantly different. Variation in TCP between 
plans increased as tumour cell load increased or radiation dose decreased. Conclusions: When using 
IMRT for AC, contour variations generated from a common protocol within the limits of minor deviations 
do not appear to have a significant impact on TCP. Contouring variations may be more critical with 
increasing tumour cell load or reducing radiotherapy dose. 
Disciplines 
Engineering | Science and Technology Studies 
Publication Details 
Jones, M. P., Martin, J., Foo, K., Estoesta, P., Holloway, L. & Jameson, M. (2018). The impact of contour 
variation on tumour control probability in anal cancer. Radiation Oncology, 13 (1), 97-1-97-7. 
Authors 
Michael Jones, Jarad Martin, Kerwyn Y. Foo, Patrick Estoesta, Lois C. Holloway, and Michael Jameson 
This journal article is available at Research Online: https://ro.uow.edu.au/eispapers1/1710 
RESEARCH Open Access
The impact of contour variation on tumour
control probability in anal cancer
Michael P. Jones1,2* , Jarad Martin1,2, Kerwyn Foo3, Patrick Estoesta3, Lois Holloway4,5,6,7,8 and Michael Jameson4,5,6
Abstract
Background: While intensity modulated radiotherapy (IMRT) has been widely adopted for the treatment of anal
cancer (AC), the added contour complexity poses potential risks. This study investigates the impact of contour
variation on tumour control probability (TCP) when using IMRT for AC.
Methods: Nine Australian centres contoured a single computed tomography dataset of a patient with AC. The same
optimised template-based IMRT planning protocol was applied to each contour set to generate nine representative
treatment plans and their corresponding dose volume histograms. A geometric analysis was performed on all
contours. The TCP was calculated for each plan using the linear quadratic and logitEUD model.
Results: The median concordance index (CI) for the bladder, head and neck of femur, bone marrow, small bowel and
external genitalia was 0.94, 0.88, 0.84, 0.65 and 0.65, respectively. The median CI for the involved nodal, primary tumour
and elective clinical target volumes were 0.85, 0.77 and 0.71, respectively. Across the nine plans, the TCP was not
significantly different. Variation in TCP between plans increased as tumour cell load increased or radiation dose decreased.
Conclusions: When using IMRT for AC, contour variations generated from a common protocol within the limits of minor
deviations do not appear to have a significant impact on TCP. Contouring variations may be more critical with increasing
tumour cell load or reducing radiotherapy dose.
Keywords: Anal cancer, Chemo-radiotherapy, Squamous cell carcinoma, Tumour control probability
Background
Squamous cell carcinoma (SCC) of the anal canal (AC)
is an uncommon tumour with an increasing incidence
[1–3]. The treatment standard is organ sparing chemo-
radiotherapy (CRT) [4, 5], which achieves loco-regional
control in 63–86% [6–8] of patients but carries a risk of
significant acute and late toxicity [9].
In RTOG 0529, Intensity Modulated Radiotherapy
(IMRT) was shown to reduce acute toxicity and cause
fewer treatment interruptions compared with historical
controls [10]. It also highlighted the increased complexity
of IMRT. Remarkably, 81% of plans required revision and
46% required multiple revisions. Despite the provision
of a contouring atlas, most revisions were required
for incorrect contouring.
Contouring errors in IMRT based CRT increase loco-
regional recurrence in head and neck SCC [11, 12]. This
raises concerns for AC patients treated with IMRT by
inexperienced clinicians. Indeed, population based data
suggests AC patients treated at high volume centres
have improved survival [13].
The Trans-Tasman Radiation Oncology Group (TROG)
investigated IMRT as a new technology in the treatment
of AC as part of their Assessment of New Radiation
Oncology Technology and Treatments (ANROTAT) [14].
Their study compared the safety, clinical efficacy and cost
effectiveness of IMRT with three-dimensional conformal
radiation therapy (3DCRT).
The credentialing component of this study involved a
benchmarking assessment performed by nine Australian
centres. Each centre was provided a computed tomog-
raphy (CT) dataset of a female patient with T3 N2 AC
(primary greater than 50 mm with involved mesorectal
and inguinal lymph nodes [LN]) to be treated with 54Gy
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in 30 fractions. Centres were asked to contour clinical
target volumes (CTV) and organs at risk (OAR).
Having acquired these contours from TROG, we
sought to describe CTV and OAR contour variability as
well as model the impact of contour variation on




Each of the nine Australian centres participating in the
TROG TRP11.A (ANROTAT) Study B contoured OAR
and CTVs using a standard protocol (Table 1) and the
Australian Gastrointestinal Trials Group (AGITG) con-
touring atlas [15].
Varian’s Eclipse treatment planning system was used to
generate nine representative IMRT plans. An optimised
template-based IMRT planning protocol was initially
applied to each contour set. If dosimetric parameters were
not met in all plans, the template was adjusted and re--
applied to all plans until all target volume and OAR con-
straints were met. Planning Target Volume (PTV)
coverage requirements and OAR constraints were based
on ANROTAT guidelines (Appendix).
Geometric analysis
All observer generated contours were collated on a
single copy of the benchmarking CT dataset. A reference
contour was generated using the STAPLE [16] algorithm
in the Computational Environment for Radiotherapy
Research (CERR) [17]. In-house code was used to
analyse the geometric variation in contours. Metrics of
comparison included two volume overlap indices; con-
cordance index (CI) and dice similarity coefficient
(DSC).
Tumour control probability
Dose volume histogram (DVH) data was extracted from
the treatment plans using CERR [17] and Matlab (The
Mathworks, Natick, USA). From the DVHs, CompPlan
[18] (open source software) calculated a TCP for each plan
using a linear quadratic and logitEUD model (shown in
Figs. 1 and 2). The models included a fraction-size effect
correction.
For the linear quadratic model where n is the number
of fractions and D’ is the total dose, an α/β ratio of
10Gy, α of 0.196 and N0 (number of initial clonogens) of
34,900 were used [19]. A sensitivity analysis investigated
the effect on TCP of increasing N0 and decreasing pre-
scription dose.
For the logitEUD model where vi is a voxel, γ50 is the
slope of the dose response curve at D50 and Di is the
total dose delivered to each voxel, D50 values (dose re-
quired for a 50% probability of tumor control at 2 years)
for gross and microscopic disease were 42Gy and 30Gy,
respectively [19]. Given these values were taken from
curves fit to patients treated with CRT, the effect of con-
current chemotherapy was implicitly incorporated.
Results
Geometric analysis
Table 2 shows the results of the OAR geometric ana-
lysis. There was close contour agreement for the blad-
der (median concordance index [CI] 0.94), head and
neck of femur (CI 0.88) and bone marrow (CI 0.84).
Greater contour variation was seen in the small bowel
(CI 0.65) and external genitalia (CI 0.65).
Table 3 shows the results of the tumour volume geo-
metric analysis. Increasing contour variation was seen in
CTV54n (CI 0.85), CTV54p (CI 0.77) and CTV45 (CI 0.
71), respectively. The CTV45 and CTV54p contours are
shown in Fig. 3.
Tumour control probability
The TCP for CTVs are shown in Table 3. Using the lin-
ear quadratic model, the median TCP for CTV45,
CTV54p and CTV54n was 0.84 (standard deviation
[SD] 0.18), 0.94 (SD 0.11) and 1.00 (SD 0.00), respect-
ively. Using the logitEUD model, the median TCP for
CTV45, CTV54p and CTV54n was 0.60 (SD 0.04), 0.52
(SD 0.02) and 0.53 (SD 0.02).
Sensitivity analysis of the linear quadratic model
revealed that the TCP reduced as tumour cell load in-
creased (Fig. 4a) but variation in TCP between plans
Table 1 Tumour and organ at risk contoured volumes
Tumour Volumes Organs at Risk
Primary clinical target volume to receive
54Gy (CTV54p)
Small bowel
Nodal clinical targe volume to receive
54Gy (CTV54n)
Bladder
Elective clinical target volume to receive
45Gy (CTV45)
External genitalia
Note: CTV45 included mesorectal,
pre-sacral, internal iliac, external iliac,
obturator and inguinal lymph nodes
Head and neck of femur
Bone marrow (ilium)
Fig. 1 The linear quadratic model
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increased (Fig. 4b). Likewise, as radiation dose de-
creased, TCP reduced (Fig. 4c) and variation in TCP
between plans increased (Fig. 4d).
Discussion
Organ at risk contour variation
Our results reveal while there was good inter-observer
agreement for the bladder (CI: 0.94), head and neck of
femur (CI 0.88) and bone marrow (CI: 0.84), there was
significant contour variation in the small bowel (CI 0.65)
and external genitalia (CI: 0.65).
For the small bowel, inclusion of the large bowel, iliac
vessels, ovaries, peritoneum and muscle were common
contouring errors. The lack of oral contrast may have
contributed to these inaccuracies. Oral contrast deliv-
ered 1 h prior to CT simulation is usually recommended
to improve small bowel identification [20].
Controversy persists regarding the optimal bowel con-
touring technique. No consensus was reached by RTOG
[20] and QUANTEC [21] list dose constraints for both
bowel loops and a bowel bag. While a bowel bag
accounts for the mobility of viscera and simplifies OAR
contouring, it may have limitations for post-surgical
patients and in capturing inferior motion [22].
Misidentification of the small (60%) and large (45%)
bowel was also common in plans submitted to RTOG
0529 [23]. However, accuracy of the external genitalia
contours was not reported. In fact the RTOG pelvic
OAR contouring guidelines do not include instructions
for contouring external genitalia [20] and no consensus
guidelines exist. While United Kingdom guidelines have
been proposed [24], until consensus guidelines are for-
malised, variation in external genitalia contours is likely
to persist.
For the development and implementation of evidenced
based OAR dose constraints, consistent contouring is im-
perative [25, 26]. This is particularly true in AC IMRT where
the proximity of OAR and tumour volumes often requires a
compromise between adequate coverage and safety.
Tumour volume contour variation
Despite being provided gross tumour volumes (GTV),
variations in the protocoled CTV expansions were seen:
CTV54p (CI 0.77), CTV54n (CI 0.85) and CTV45 (CI 0.
71). Unsurprisingly, the greatest variation was seen in
the CTV45 volumes. These are the largest and the least
influenced by the GTV. Incorrect elective nodal con-
touring was also common in RTOG 0529 where errors
were seen in the mesorectum (55%), pre-sacral (43%), in-
guinal (33%) and iliac nodal groups (31%).
The greatest discrepancies in the CTV45 volumes were
in the anterior direction with variable expansion into the
uterus and bladder. The AGITG guidelines recommend
an internal margin expansion of 1 cm into the bladder
and uterus to account for bladder volume variation [15].
The greatest discrepancies in the CTV54p volumes
were also in the anterior direction with variable expan-
sion into the vagina and genitalia. Some have highlighted
the risk of genital relapse when IMRT is used to achieve
genital sparing [27]. While this has been challenged
more recently [28], we emphasise the priority of ad-
equate tumour coverage over genital sparing and stress
the importance of accurate multi-modality baseline
imaging to help optimally define the extent of disease.
Contouring atlases for anorectal volumes have been
shown to reduce inter-observer variability [29], however,
atlases were available to observers in both the RTOG and
TROG studies. Perhaps this variation can be attributed to
clinicians coming to terms with a new technique.
Fig. 2 The logitEUD model
Table 2 Organ at risk geometric analysis
Organs at Risk Stats CI DSC Volume (cm3)
Small bowel Median 0.65 0.79 543.22
Range 0.12 0.10 132.37
Bladder Median 0.94 0.97 156.37
SD 0.01 0.01 6.43
External genitalia Median 0.65 0.79 130.61
SD 0.19 0.17 65.47
Head and neck of femur Median 0.88 0.93 202.29
SD 0.06 0.03 23.73
Bone marrow (ilium) Median 0.84 0.91 371.61
SD 0.06 0.03 22.62
SD: standard deviation, CI: concordance index, DSC: dice similarity coefficient
Table 3 Tumour control probability and tumour volume
geometric analysis
Volume Stats TCP (LQ) TCP (Logit) CI DSC Volume
(cm3)
CTV45 Median 0.84 0.60 0.71 0.82 1299.38
SD 0.18 0.04 0.13 0.10 190.64
CTV54p Median 0.94 0.52 0.77 0.86 458.83
SD 0.11 0.02 0.17 0.13 132.92
CTV54n Median 1.00 0.53 0.85 0.89 37.92
SD 0.00 0.02 0.26 0.21 7.69
CTV45: elective clinical targe volume, CTV54p: primary clinical target volume,
CTV54n: nodal clinical target volume, SD: standard deviation, CI: concordance
index, DSC: dice similarity coefficient
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A literature review identified guidelines, teaching, auto-
contouring and multi-modality imaging as interventions
that reduce inter-observer variability in contour delineation
[30]. Online teaching and contouring workshops are now
offered by international cancer societies and clinicians can
have their volumes peer reviewed at their centre and
through participation in clinical trials incorporating radio-
therapy quality assurance.
Tumour control probability
IMRT is the treatment of choice for AC [31]. It
enhances the therapeutic window by reducing dose to
OAR and resultant acute toxicity [23]. Fewer treatment
breaks for toxicity are required and it offers the prospect
of safe dose escalation for large tumours. However, AC
contouring is complex and considerable variation exists
in target volume delineation [29, 31].
We have shown that minor contour variations gener-
ated from a common protocol do not translate into
significant differences in TCP. By applying a template-
based IMRT planning protocol, we isolated the impact
of contour variation on TCP. Further TCP variability
would be expected should centres develop their own
treatment plans or employ different treatment doses.
Fig. 3 Tumour volumes contoured by the nine participating centres. Left: Primary clinical target volumes (CTV54p), Right: Elective clinical targe
volumes (CTV45)
Fig. 4 Sensitivity analyses. a: Tumour control probability with changing N0, b: variation in tumour control probability between plans with changing N0,
c: tumour control probability with changing dose, d: variation in tumour control probability between plans with changing dose. TCP = Tumour Control
Probability, SD = Standard Deviation, N0 = number of initial clonogens, Gy = Gray, CTV54p = Primary clinical target volume to receive 54Gy,
CTV54n = Nodal clinical targe volume to receive 54Gy, CTV45 = Elective clinical target volume to receive 45Gy
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Contours for this study were generated from a com-
mon contouring guideline [14]. Contouring guidelines
lead to greater inter-observer agreement [32] and the
provision of an anorectal contouring atlas has been
shown to increase TCP and reduce normal tissue com-
plication probability (NTCP) [29].
GTV contours were supplied in the TROG study
which may have reduced CTV variation. Inaccurate
GTV delineation occurred in 21% of plans submitted to
RTOG 0529 [23]. Target volume delineation is more
accurate with the use of co-registered Positron Emission
Tomography (PET) and Magnetic Resonance Imaging
(MRI) and is recommended for treatment planning [31].
PET is recommended to identify lymph nodes requiring
inclusion in the GTV [33].
Sensitivity analysis
We investigated the influence of prescription dose and
N0 (number of initial clonogens) on the TCP predicted
by the linear quadratic model. Increasing N0 led to a
reduction in TCP (Fig. 4a) and an increase in the TCP
variation between plans (Fig. 4b). Decreasing dose led to
a reduction in TCP (Fig. 4c) and increase in TCP vari-
ation between plans (Fig. 4d).
While the influence of dose and N0 on the absolute
TCP is not surprising, the effect on TCP variation is
quite interesting. It suggests contour variations become
more critical as one moves down the dose response
curve either by increasing tumour cell load or reducing
dose. These are important insights for radiation dose de-
escalation trials such as ACT 3 and 4 [34] and highlights
the central role real-time radiotherapy quality assurance
should play in these studies.
Limitations and future directions
In radiation therapy, TCP models have traditionally been
limited to the relative comparison of treatment plans
rather than their absolute predictive power. Indeed, the
difference in tumour control estimated by the two
models used in our study highlights the dangers of over
interpreting TCP results or using them to inform radio-
therapy dose selection.
That contours were completed in the context of a trial
using a common protocol with a GTV already provided
is a shortcoming of this study potentially limiting its
applicability to the wider community. Our results are
likely to underestimate contour variation and do not
capture the effect of radiotherapy plan generation.
Our study aim was to isolate the impact of contour
variation on TCP. While we appreciate there is manual
bias in planning [35], it is out of the scope of this study.
We tried to mitigate against this by using a single plan-
ner and single patient anatomy, deploying a class solu-
tion beam arrangement, objectives and priorities.
While a NTCP assessment was explored, this was
abandoned due to a lack of reliable radiobiological pa-
rameters in the literature. The principle benefit of IMRT
is reduced OAR dose, avoidance of toxicity induced
treatment gaps and the prospect of safe dose escalation for
larger tumours. To achieve this, tumour volumes must bal-
ance adequate coverage of at risk sites with toxicity risk.
The ACT 3–5 [34] studies will provide valuable in-
sights into the radiation dose response curve for AC.
The incorporation of prognostic factors other than stage
such as human papilloma virus status could help further
refine this relationship [36]. Treatment adaptation repre-
sents another promising approach and may ultimately
provide the best means of individualising treatment [37].
Conclusions
In the context of a clinical study, with the dose and
parameters used, minor contour variations generated
from a common guideline did not significantly impact
TCP. With increasing tumour cell load or reducing RT
dose, contour variations may be more critical.
Appendix
Volume Constraint
PTV 45 D95≥ 40.5Gy
D98≥ 36Gy
D98≥ 36Gy
PTV 54 D95≥ 48.6
D98≥ 43.2Gy
D2%≤ 62.1Gy
Small bowel V30Gy≤ 200 cm3
V35Gy≤ 150 cm3
V45Gy≤ 20 cm3
V50Gy = 0 cm3
Femoral heads V30Gy≤ 50%
V40Gy≤ 35%
V44Gy≤ 5%
Iliac crest V30Gy≤ 50%
V40Gy≤ 35%
V50Gy≤ 5%






Jones et al. Radiation Oncology  (2018) 13:97 Page 5 of 7
Abbreviations
3DCRT: Three-dimensional conformal radiation therapy; AC: Anal cancer;
AGITG: Australian Gastrointestinal Trials Group; ANROTAT: Assessment of New
Radiation Oncology Technology and Treatments; CERR: Computational
Environment for Radiotherapy Research; CI: Concordance Index; CRT: Chemo-
radiotherapy; CT: Computed tomography; CTV: Clinical target volume;
CTV45: Elective clinical target volume to receive 45Gy; CTV54n: Nodal clinical
target volume to receive 54Gy; CTV54p: Primary clinical target volume to
receive 54Gy; DSC: Dice similarity coefficient,; DVH: Dose Volume Histogram;
GTV: Gross tumour volumes,; IMRT: Intensity modulated radiotherapy;
LN: Lymph node; MRI: Magnetic Resonance Imaging; OAR: Organs at risk;
PET: Positron Emission Tomography; PTV: Planning Target Volume;
SCC: Squamous cell carcinoma; SD: Standard Deviation; TCP: Tumour Control
Probability; TROG: Trans-Tasman Radiation Oncology Group
Acknowledgements
The authors acknowledge the Trans-Tasman Radiation Oncology group
(TROG).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
KF conceived of the study and generated the IMRT plans with PE. JM provided
expert opinion on anal cancer management. MJ and LH performed the
geometric and tumour control probability analysis. MPJ wrote the protocol,
consolidated the data and wrote the manuscript. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
Consent was obtained from the Trans-Tasman Radiation Oncology group
(TROG) to use the Assessment of New Radiation Oncology Technology and
Treatments (ANROTAT) data.
Competing interests
The authors declare that they have no competing interests.
Author details
1School of Medicine and Public Health, University of Newcastle, Callaghan,
NSW, Australia. 2Department of Radiation Oncology, Calvary Mater Newcastle,
Waratah, NSW, Australia. 3Department of Radiation Oncology, Chris O’Brien
Lifehouse, Camperdown, NSW, Australia. 4Liverpool and Macarthur Cancer
Therapy Centres, Liverpool, NSW, Australia. 5Ingham Institute for Applied
Medical Research, Liverpool, NSW, Australia. 6South West Clinical School,
Faculty of Medicine, University of New South Wales, Kensington, NSW,
Australia. 7Institute of Medical Physics, School of Physics, University of
Sydney, Camperdown, NSW, Australia. 8Centre for Medical Radiation Physics,
University of Wollongong, Wollongong, NSW, Australia.
Received: 14 November 2017 Accepted: 18 April 2018
References
1. Steele SR, Varma MG, Melton GB, Ross HM, Rafferty JF, Buie WD. Practice
parameters for anal squamous neoplasms. Dis Colon rectum. 2012;55:735–49.
2. Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of
Anal Canal carcinoma in the United States. J Clin Oncol. 2013;31:1569–75.
3. Jemal A, Simard EP, Dorell C, Noone A-M, Markowitz LE, Kohler B, Eheman C,
Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ,
Schymura MJ, Anderson RN, Yankey D, Edwards BK. Annual report to the
nation on the status of Cancer, 1975-2009, featuring the burden and trends in
human papillomavirus(HPV)-associated cancers and HPV vaccination coverage
levels. JNCI Journal of the National Cancer Institute. 2013;105:175–201.
4. National Comprehensive Cancer Network: Anal Carcinoma (Version 2.2017)
https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. 2017.
5. Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold
D, ESMO, ESSO, ESTRO: Anal cancer: ESMO-ESSO-ESTRO clinical practice
guidelines for diagnosis, treatment and follow-up. Radiother oncol. 2014;11:
330–39.
6. Martenson JA, Lipsitz SR, Lefkopoulou M, Engstrom PF, Dayal YY, Cobau CD,
Oken MM, Haller DG. Results of combined modality therapy for patients
with anal cancer (E7283). An eastern cooperative oncology group study.
Cancer. 1995;76:1731–6.
7. Peiffert D, Seitz JF, Rougier P, Francois E, Cvitkovic F, Mirabel X, Nasca S,
Ducreux M, Hannoun-Levi JM, Lusinchi A, Debrigode E, Conroy T, Pignon JP,
Gerard JP. Preliminary results of a phase II study of high-dose radiation
therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP
chemotherapy for patients with anal canal cancer: a French cooperative
study. Ann Oncol. 1997;8:575–81.
8. Gerard JP, Ayzac L, Hun D, Romestaing P, Coquard R, Ardiet JM, Mornex F.
Treatment of anal canal carcinoma with high dose radiation therapy and
concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Radiother Oncol. 1998;46:249–56.
9. Bentzen AG, Guren MG, Vonen B, Wanderås EH, Frykholm G, Wilsgaard T, Dahl
O, Balteskard L. Radiotherapy and oncology. Radiother Oncol. 2013;108:55–60.
10. Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J,
Haddock MG, Rotman M, Parikh PJ, Safran H, Willett CG. RTOG 0529: a phase
2 evaluation of dose-painted intensity modulated radiation therapy in
combination with 5-fluorouracil and mitomycin-C for the reduction of acute
morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;
86:27–33.
11. Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J,
Yuen K, Fisher R, Rischin D. Critical impact of radiotherapy protocol
compliance and quality in the treatment of advanced head and neck
Cancer: results from TROG 02.02. J Clin Oncol. 2010;28:2996–3001.
12. Chen AM, Chin R, Beron P, Yoshizaki T, Mikaeilian AG, Cao M. Inadequate
target volume delineation and local-regional recurrence after intensity-
modulated radiotherapy for human papillomavirus-positive oropharynx
cancer. Radiother Oncol. 2017;123:412–8.
13. Amini A, Jones BL, Ghosh D, Schefter TE, Goodman KA. Impact of facility
volume on outcomes in patients with squamous cell carcinoma of the anal
canal: analysis of the National Cancer Data Base. Cancer. 2017;123:228–36.
14. Trans Tasman Radiation Oncology Group: The assessment of new radiation
oncology technologies and treatments (ANROTAT): study protocol B (IMRT
Anal Canal) final report. 2012.
15. Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan
S, Kachnic L. Australasian gastrointestinal trials group (AGITG) contouring
atlas and planning guidelines for intensity-modulated radiotherapy in anal
cancer. Radiat Oncol Biol. 2012;83:1455–62.
16. Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level
estimation (STAPLE): an algorithm for the validation of image segmentation.
IEEE Trans Med Imaging. 2004;23:903–21.
17. Deasy JO, Blanco AI, Clark VH. CERR: a computational environment for
radiotherapy research. Med Phys. 2003;30:979–85.
18. Holloway LC, Miller J-A, Kumar S, Whelan BM, Vinod SK. Comp plan: a
computer program to generate dose and radiobiological metrics from
dose-volume histogram files. Med Dosim. 2012;37:305–9.
19. Muirhead R, Partridge M, Hawkins MA. A tumor control probability model
for anal squamous cell carcinoma. Radiother Oncol. 2015;116:192–6.
20. Gay HA, Barthold HJ, O'Meara E, Bosch WR, Naqa El I, Al-Lozi R, Rosenthal
SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett
C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W, Gaffney D,
Viswanathan AN, Michalski JM. Pelvic normal tissue contouring guidelines
for radiation therapy: a radiation therapy oncology group consensus panel
atlas. Int J Radiat Oncol Biol Phys. 2012;83:e353–62.
21. Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Haken Ten RK, Miften M.
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat
Oncol Biol Phys. 2010;76:S101–7.
22. Dominello MM, Nalichowski A, Paximadis P, Kaufman I, McSpadden E, Joiner
M, Miller S, Konski A. Limitations of the bowel bag contouring technique in
the definitive treatment of cervical cancer. Practical Radiation Oncology.
2014;4:e15–20.
23. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL,
Willins JD, Ryan DP, Hong TS. Dose-painted intensity-modulated
radiation therapy for anal Cancer: a multi-institutional report of acute
toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82:
153–8.
24. Brooks C, Hansen VN, Riddell A, Harris VA, Tait DM. Proposed genitalia
contouring guidelines in anal cancer intensity-modulated radiotherapy. Br J
Radiol. 2015;88:20150032–7.
Jones et al. Radiation Oncology  (2018) 13:97 Page 6 of 7
25. Brown E, Cray A, Haworth A, Chander S, Lin R, Subramanian B, Ng M. Dose
planning objectives in anal canal cancer IMRT: the TROG ANROTAT
experience. J Med Radiat Sci. 2015;62:99–107.
26. Hornby CJ, Ackerly T, See A, Geso M. Exploring the effect of marked normal
structure volume on normal tissue complication probability. Med Dosim.
2003;28:223–7.
27. Koeck J, Lohr F, Buergy D, Büsing K, Trunk MJ, Wenz F, Mai S. Genital invasion
or perigenital spread may pose a risk of marginal misses for intensity
modulated radiotherapy (IMRT) in anal cancer. Radiat Oncol. 2016:1–8.
28. Koeck J, Lohr F, Buergy D, Büsing K, Trunk MJ, Wenz F, Mai S. Genital
invasion or perigenital spread may pose a risk of marginal misses for
Intensity Modulated Radiotherapy (IMRT) in anal cancer. Radiat Oncol. 2016;
11:53.
29. Dell’Acqua V, Kobiela J, Kraja F, Leonardi MC, Surgo A, Zerella MA, Arculeo S,
Fodor C, Ricotti R, Zampino MG, Ravenda S, Spinoglio G, Biffi R, Bazani A,
Luraschi R, Vigorito S, Spychalski P, Orecchia R, Glynne-Jones R, Jereczek-
Fossa BA. Genital marginal failures after intensity-modulated radiation
therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when
compared to 3DCRT. Medical Oncology. 2018;35:59.
30. Vinod SK, Min M, Jameson MG, Holloway LC. A review of interventions to
reduce inter-observer variability in volume delineation in radiation oncology.
Journal of Medical Imaging and Radiation Oncology. 2016;60:393–406.
31. Glynne-Jones R, Tan D, Hughes R, Hoskin P. Squamous-cell carcinoma of the
anus: progress in radiotherapy treatment. Nat Rev Clin Oncol. 2016;13:447–59.
32. Fuller CD, Nijkamp J, Duppen JC, Rasch CRN, Thomas CR, Wang SJ, Okunieff
P, Jones WE, Baseman D, Patel S, Demandante CGN, Harris AM, Smith BD,
Katz AW, McGann C, Harper JL, Chang DT, Smalley S, Marshall DT, Goodman
KA, Papanikolaou N, Kachnic LA, Radiation Oncology Committee of the
Southwest Oncology Group. Prospective randomized double-blind pilot
study of site-specific consensus atlas implementation for rectal cancer
target volume delineation in the cooperative group setting. Int J Radiat
Oncol Biol Phys. 2011;79:481–9.
33. Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET
in the initial staging and response assessment of anal Cancer: a systematic
review and meta-analysis. Ann Surg Oncol. 2015;22:3574–81.
34. PLATO: Personalising anal cancer radiotherapy dose http://www.isrctn.com/
ISRCTN88455282?q=&filters=conditionCategory:Cancer&sort=&offset=
6&totalResults=1847&page=1&pageSize=20&searchType=basic-search.
35. Batumalai V, Jameson MG, Forstner DF, Vial P, Holloway LC. How important
is dosimetrist experience for intensity modulated radiation therapy? A
comparative analysis of a head and neck case. Practical Radiation Oncology.
2013;3:e99–e106.
36. Gilbert DC, Williams A, Allan K, Stokoe J, Jackson T, Linsdall S, Bailey CM,
Summers J. p16INK4A, p53, EGFR expression and KRAS mutation status in
squamous cell cancers of the anus: correlation with outcomes following
chemo-radiotherapy. Radiother Oncol. 2013;109:146–51.
37. Jones M, Hruby G, Stanwell P, Gallagher S, Wong K, Arm J, Martin J.
Multiparametric MRI as an outcome predictor for anal canal cancer
managed with chemoradiotherapy. BMC Cancer. 2015;15:281.
Jones et al. Radiation Oncology  (2018) 13:97 Page 7 of 7
